Eli Lilly $1 Trillion Market Cap

Eli Lilly & Co. (LLY) reached a $1 trillion market capitalization on Nov. 21, 2025, becoming the first drugmaker to join the trillion-dollar club as strong demand for its GLP-1 drugs Zepbound and Mounjaro and a new federal pricing plan lifted its valuation.

Trillion-Dollar Milestone and Federal Pricing Plan

Eli Lilly became the first pharmaceutical and health-care company to surpass a $1 trillion market value, joining a group previously dominated by technology firms. The surge reflected heavy demand for Lilly’s GLP-1-based weight-loss drug Zepbound and its diabetes treatment Mounjaro. Nearly 12% of Americans—about 40 million people—have used a GLP-1 drug for weight loss, demonstrating broad consumer adoption.

A federal pricing plan announced in early November 2025 aims to expand access by negotiating discounts with manufacturers, including Lilly. Under the plan, Zepbound and other GLP-1 drugs will be available for about $350 per month through a new direct-to-consumer platform called TrumpRx and for roughly $245 per month through Medicare, with copays near $50 for Medicare enrollees. Officials expect the pricing changes and platform rollout to begin in early 2026.

An investigational oral GLP-1 from Lilly, orforglipron, is pending FDA approval and would be included in the discounted pricing if cleared. Lilly has not issued new formal financial guidance in the past 72 hours.